GeneNews holders okay stock consolidation

Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe that [...]

GeneNews launches SentinelGx

GeneNews (TSX: GEN) has launched SentinelGx, a suite of pharmacogenomic and companion diagnostic BloodRNA services for drug development and personalized health management applications. SentinelGx services provide complete whole blood transcriptome analysis for RNA expression profiling of inflammatory pathways, immune system response and cell signalling based on the company’s patented Sentinel Principle technology. A catalog of [...]

DiaMedica appoints Dr. Paul Burn to SAB

DiaMedica (TSX:DMA) has appointed Dr. Paul Burn to its scientific advisory board. Dr. Burn currently serves as the Broin chair and director for The Sanford Project, an emerging translational research center focused on identifying and delivering a cure for Type 1 diabetes. “Dr. Burn is a highly regarded key opinion leader in diabetes research and [...]

Neoprobe to unveil new brand identity

Neoprobe (NASDAQ:NEOP) expects to announce in the coming weeks a new brand identity to mark a “formal turning point in the recognition of Neoprobe as a precision diagnostics company focused on the radiopharmaceutical space,” CEO Dr. Mark Pykett said in the quarterly report. During the third quarter, the company its GDS line of gamma detection [...]

Rodman starts Celsion at market outperform

Rodman & Renshaw has initiated coverage of Celsion (NASDAQ:CLSN) with a “market outperform/speculative risk” rating and a target price of $6, based on a discounted revenues and earnings per share valuation methodology. The stock closed at $2.75 on Tuesday. “With approximately $25 million in cash pro forma, and an enterprise value of $47 million, we [...]

Cipher readies regulatory filings for acne product

Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million milestone payment from its U.S. partner. The FDA review under PDUFA is expected to be six months. “With Lipofen generating steady revenue and our tramadol product [...]

BioSante to present at BIO Investor Forum

BioSante Pharmaceuticals (NASDAQ:BPAX) CEO Stephen Simes will speak at the BIO Investor Forum in San Francisco this afternoon. He will provide a company overview as well as an update on the LibiGel Phase 3 clinical development program and planned new drug application submission. A live audio webcast of remarks by Mr. Simes at BIO Investor [...]

Roth starts med tech focus list

Roth Capital Partners has established a medical technology focus list, highlighting stocks that it believes offer attractive near-term trading opportunities. Roth launched the focus list with “buy” rated AtriCure (NASDAQ:ATRC). Last week, Roth raised its target price on AtriCure to to $15 from $13.50, heading into the company’s FDA advisory panel meeting tomorrow. The stock [...]

Soricimed in-licenses peptide from UHN

Closely held Soricimed Biopharma has in-licensed a proprietary peptide from the University Health Network, which was developed by Dr. Mansoor Husain at his lab at the University of Toronto. “Dr. Husain looked at a series of cell lines and showed that the peptide was able to stop growth in cervical, bone and lung cancer cells,” [...]

Interface in licensing pact with Navilyst Medical

Closely held Interface Biologics has reached a definitive license and supply agreement with Navilyst Medical, giving it exclusive access to incorporate Interface’s Endexo technology in its vascular access products. Navilyst Medical is a leading manufacturer of image-guided medical technologies. Endexo is a bio-medical polymer additive that results in a passivating surface that reduces platelet adhesion, [...]

Next Page »